What Predicts a Better Outcome in Psychedelic-Assisted Therapy?
For years, psychedelic research has focused heavily on the medicine itself: the compound, the dose, the acute subjective experience, and the resulting changes in symptoms.
A new study suggests that the more important question may be broader.
Who is receiving the treatment, how prepared are they, and what happens within the therapeutic relationship may matter substantially to the outcome.
Published April 29, 2026, in Nature Mental Health, the study surveyed 158 therapists working with psychedelic-assisted therapy to identify baseline, preparation, and session factors they believed were associated with favorable or unfavorable long-term outcomes. It is the largest survey of psychedelic therapists examining these perceived predictors to date.
The findings do not establish causal predictors of treatment response. They are therapist-reported perceptions, not prospective patient-outcome data.
But they identify a set of factors that deserve much closer attention as psychedelic-assisted therapy moves toward a more mature clinical model.
The Therapeutic Relationship Came First
Among the factors rated by therapists, strong therapeutic alliance received the highest rating as a predictor of favorable long-term outcomes.
That finding is notable because psychedelic medicine is sometimes discussed as though the pharmacological intervention is the primary therapeutic agent and the therapist's role is secondary.
The findings point in a different direction.
Therapists also placed high importance on robust social support, openness to experience, the capacity to surrender, secure attachment, and a belief in an active therapeutic mechanism.
Several of these factors are not unique to psychedelic-assisted therapy.
Therapeutic alliance, social connection, attachment, patient expectations, and psychological readiness have long been relevant to psychotherapy and other forms of mental health treatment. One of the study's authors, Max Wolff, noted that many of the highest-rated factors correspond to established predictors of treatment response in conventional psychotherapy.
This raises an important possibility.
Psychedelic-assisted therapy may not be as clinically distinct from psychotherapy as the intensity of the psychedelic experience sometimes suggests.
The medicine may open a particular therapeutic window. What happens within that window may still depend heavily on the conditions surrounding it.
The Top Predictors Were Largely Relational and Psychological
The therapist ratings identified several factors associated with favorable outcomes.
Among the highest-rated were:
Strong therapeutic alliance
High openness to experience
High capacity to surrender
Belief in an active role in one's own healing
High personality functioning
Regular contact with family and friends
Previous positive response to psychotherapy
Secure attachment style
Previous breathwork experience
Previous meditation experience
The pattern is striking.
Many of the strongest signals do not describe the psychedelic substance at all.
They describe the person, the therapeutic relationship, and the context in which the intervention occurs.
This does not mean that these factors have been proven to cause better outcomes. The study was cross-sectional and asked therapists to rate their perceptions of potential predictors. The next step, as the researchers emphasize, is to determine whether these factors actually predict long-term patient outcomes when measured prospectively.
That distinction is essential.
A clinician's experience can generate an important hypothesis. It cannot, by itself, establish causation.
Preparation May Be Part Of The Treatment, Not Simply The Prelude To It
The study also highlights the importance therapists placed on preparation, patient mindset, integration, and environmental context.
This has practical implications for how psychedelic-assisted therapy is conceptualized.
Preparation is sometimes treated administratively: reviewing expectations, explaining what may happen during dosing, discussing logistics, and establishing safety procedures.
A more clinically substantive view is possible.
Preparation can establish the therapeutic frame before the psychedelic experience begins. It can clarify intentions without imposing expectations, establish boundaries, identify potential sources of distress, and begin building the relational conditions in which difficult material can be approached.
The distinction matters because psychedelic experiences can involve heightened emotional responsiveness, altered perception, autobiographical material, and experiences that patients may interpret as psychologically or spiritually significant.
The clinician's responsibility is not to dictate what those experiences mean.
It is to create conditions in which the patient can encounter them safely and work with their implications afterward.
Surrender Is Not The Same As Passivity
One of the study's more interesting findings was the high rating given to a patient's capacity to surrender.
The term requires clinical precision.
Surrender should not be understood as abandoning agency or relinquishing informed consent. In a clinical context, the capacity to surrender can instead describe an individual's ability to reduce excessive attempts to control the unfolding experience while maintaining sufficient psychological safety and orientation to engage with it.
That distinction is particularly important in psychedelic-assisted therapy.
The therapeutic task is not simply to produce an intense experience. Nor is it to ensure that every experience feels pleasant.
Patients may encounter grief, fear, memories, bodily sensations, interpersonal themes, or other psychologically challenging material.
A practitioner who understands surrender as passive compliance may approach these moments very differently from one who understands it as a temporary willingness to allow experience to unfold without unnecessary resistance.
The latter interpretation is closer to the clinical question raised by this research: what psychological capacities may help a person engage productively with the experience?
Social Support Appeared Alongside Therapeutic Alliance
The study also rated robust social support highly as a favorable factor.
This is clinically significant because treatment does not occur in isolation.
Whatever changes occur during psychedelic-assisted therapy eventually have to be incorporated into ordinary life: relationships, work, family systems, routines, identity, and ongoing mental health care.
A powerful session does not automatically produce durable behavioral change.
The surrounding environment may determine whether insights can be translated into sustained changes in how a person relates to themselves and others.
This is one reason integration deserves to be understood as more than a conversation about what happened during dosing.
Integration is where experience meets the rest of a person's life.
The Findings Differed By Substance And Treatment Setting
The study also found meaningful differences depending on the context in which therapists practiced.
Therapists working primarily with psilocybin placed greater emphasis on preparation and therapeutic presence than therapists working primarily with ketamine. Therapists working in unregulated settings also rated certain challenging features of psychedelic experiences more favorably.
These differences should not be interpreted as evidence that one treatment model is superior.
They do, however, demonstrate that psychedelic-assisted therapy is not a single uniform intervention.
The pharmacology, dosing model, duration, subjective effects, therapeutic framework, practitioner training, regulatory environment, and patient population can all differ.
Clinical protocols therefore cannot simply treat "psychedelic therapy" as one homogeneous category.
Precision matters.
One Unfavorable Factor Stood Out
The strongest-rated unfavorable predictor was prior use of nonpsychedelic substances.
This finding deserves careful interpretation.
The study does not establish that prior substance use causes poorer outcomes, nor does it establish that a history of substance use should automatically exclude someone from psychedelic-assisted therapy.
Rather, it reflects how therapists perceived the relationship between prior nonpsychedelic substance use and treatment response.
That distinction becomes particularly important when translating research findings into screening protocols.
Screening should identify clinically relevant risks and determine whether a particular intervention is appropriate for a particular patient. It should not turn observational or therapist-reported associations into categorical rules without supporting clinical evidence.
What This Study Changes
The most important contribution of this research may be conceptual.
Psychedelic-assisted therapy is often framed around the question:
What does the psychedelic do?
The findings suggest that clinical research should increasingly ask:
What conditions allow the psychedelic-assisted intervention to work well?
That means studying pharmacology alongside therapeutic alliance.
It means examining preparation alongside dose.
It means considering attachment, social support, expectations, psychological readiness, therapeutic presence, and integration alongside acute subjective effects.
And it means moving toward prospective research capable of determining which of these factors actually predict patient outcomes rather than relying solely on expert perception.
The researchers explicitly identify this as the next step: linking the therapist-rated predictors to actual long-term patient outcomes.
That is where the field's next generation of evidence needs to go.
The Clinician May Be Part Of The Mechanism
There is a deeper implication here.
If the therapeutic relationship, preparation, psychological readiness, and social environment meaningfully influence outcomes, then the practitioner is not simply present while the medicine acts.
The practitioner is part of the clinical environment in which the intervention unfolds.
That does not diminish the importance of pharmacology. It makes the clinical system more complete.
Psychedelic-assisted therapy asks clinicians to work at an unusual intersection: pharmacology and psychotherapy, neurobiology and relationship, protocol and presence.
The goal is not to make the psychedelic experience more dramatic.
It is to create the conditions in which meaningful therapeutic change can be approached with rigor, safety, and respect for the patient's autonomy.
The science is increasingly giving us reason to look beyond the molecule.
What happens in the room may matter.
Who is in the room may matter.
And how prepared they are to meet what emerges may matter most of all.
Primary source:
Viljoen, G., Bendau, A., Walter, H., et al. "Therapist-rated predictors of response to psychedelic-assisted therapy."Nature Mental Health, 4, 951–961 (2026). Published April 29, 2026.
Read the full study in Nature Mental Health
The study's anonymized therapist-level dataset is also publicly available through Figshare.
Additional source:
A study author, Max Wolff, summarized the study's top-rated predictors and emphasized the overlap between these factors and established predictors in conventional psychotherapy.
